Modality
Cell Therapy
MOA
SHP2i
Target
GPRC5D
Pathway
Proteasome
GA
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
Jun 2024
→ Jul 2030
Phase 1Current
NCT07193676
423 pts·GA
2024-11→2027-06·Terminated
NCT04625722
953 pts·GA
2024-06→2030-07·Completed
1,376 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-06-141.2y awayPh2 Data· GA
2030-07-204.3y awayPh2 Data· GA
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Complet…
P1/2
Termina…
Catalysts
Ph2 Data
2027-06-14 · 1.2y away
GA
Ph2 Data
2030-07-20 · 4.3y away
GA
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07193676 | Phase 1/2 | GA | Terminated | 423 | PASI75 |
| NCT04625722 | Phase 1/2 | GA | Completed | 953 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Doxacagene | Sanofi | Approved | PSMA | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn |